In CD4+ T cells, CIT highlighted site-specific DNAm as a probable regulatory intermediate between risk variant-meQTLs and eQTMs at 5 risk loci (FDR < 0.05), implicating ANKRD55, JAZF1, ORMDL3, FCRL3, IL6ST, C11orf10, TAX1BP1, and GSDMB as genes with potential to confer perturbed immune function via this mechanism in RA. The gene discussed is JAZF1; the disease is rheumatoid arthritis.